Minimal residual disease follow-up in 2HOX11L2-expressing patients.

Patient UPNT18 had a relapse 10 months after CR1. CR2 was achieved 4 months later. A second relapse occurred 16 months after diagnosis but could not be investigated. Patient UPNT18 remained in CR for 10 months after the beginning of treatment. Values are 8.8 and 10HOX11L2 normalized copy number for the 2 CR1 samples of UPNT18 and 0.3, 0.15, and 0.16 for the 3 CR1 samples of UPNT24.